Takeda's Maribavir Hits Primary Endpoint Goal In Late-Stage Study In Transplant RecipientsBenzinga • 02/12/21
Takeda's Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/DiseaseBusiness Wire • 02/12/21
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn's DiseaseBusiness Wire • 02/10/21
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/05/21
Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPSBusiness Wire • 02/04/21
Data at EAHAD 2021 Highlight Value of Takeda's Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused AdvancementsBusiness Wire • 02/03/21
Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based ChemotherapyBusiness Wire • 01/28/21
Takeda's Entyvio SC and Celltrion's Remsima SC EU5 Launches Have Benefitted from Parent Brand Reputation, New Clinical Data, and COVID-19 Restraints, According to Spherix Global InsightsPRNewsWire • 01/20/21
Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50% by FY2030 at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/11/21
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USDBusiness Wire • 12/21/20
U.S. FDA Approves Supplemental New Drug Application for Takeda's ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CMLBusiness Wire • 12/18/20
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda's TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic EsophagitisBusiness Wire • 12/15/20
Takeda's Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next DecadeBusiness Wire • 12/09/20